Addiction Research Jobs in Missouri (NOW HIRING)

The Department of Pediatrics at Children’s Mercy seeks a creative and scholarly leader to serve as Division Director of Clinical Pharmacology, Toxicology, and Therapeutic Innovation. The Division Director will be responsible for leading the research, educational, and quality missions of Clinical Pharmacology, an academic division focused on providing clinical consultation and research programs aimed at making the use of medications in children safer and more effective. Within the division, the Section of Medical Toxicology provides consultative services for potential poison exposures, including overdoses, environmental exposures, and envenomations. The Division Director will foster collaborative ties throughout Children’s Mercy, bridging the division’s research missions in genomic, clinical research, and translational interests across the Department of Pediatrics and CMRI.

This is a faculty position offering academic appointments at the University of Missouri – Kansas City School of Medicine and the Kansas University School of Medicine, rank to be commensurate with experience. Kansas City’s strong culture of philanthropy has led to the creation of many endowed roles available to distinguished and accomplished leaders. An endowed position may be extended to the selected candidate, contingent upon their qualifications and record of achievement.

Established in 1996, Clinical Pharmacology has a national and international reputation for impactful translational science and excellence in training. The Division has a strong record for successful extramural funding and an outstanding publication record. Clinical Pharmacology faculty and staff are national leaders in pharmacogenetics, institutional leaders in health equity research, and outstanding clinicians, using pharmacology and toxicology to improve the care of patients. Among the groups in the Division are:

• GOLDILOKs Clinic (GOLDILOKS® stands for Genomic- and Ontogeny- Linked Dose Individualization and cLinical Optimization for KidS). A multidisciplinary clinic with a pediatrician, clinical pharmacist, and nurse who see patients with a variety of conditions including adverse drug reactions, drug-drug interactions, and medication nonresponse. Additionally, the clinical staff meet weekly with genetics lab experts and a social worker to discuss upcoming patients and formulate a multidisciplinary care plan individualized to each patient. The clinic offers educational opportunities to pharmacy students, medical students, residents, and fellows.
• The Medical Toxicology Consult Team provides consultative services for a variety of environmental, exposure, overdose and poison issues. A Children’s Mercy Medical Toxicologist is on call 24 hours a day, seven days a week. Our toxicologists also provide medical direction for the Kansas Poison Control Center. This service on average has 150-200 bedside consults per year. Academically, the toxicologists provide lectures to CMH Pediatric Emergency Medicine fellows and residents, CMH Pediatric Medicine fellows, TMC/University Health Emergency Medicine residents, and 5th/6th year UMKC medical students. In continuing the collaboration of research, Kansas Fights Addiction Grant-Opioid Withdrawal Treatment Clinical Practice Guideline was rewarded.
• Children’s Mercy Hospital (CMH) Pediatric Clinical Pharmacology (T32) training program is the Division of Clinical Pharmacology and Toxicology at CMH one of the largest and most comprehensive Pediatric Clinical Pharmacology programs in North America. Our fellowship training program is accredited by the American Board of Clinical Pharmacology (ABCP) and has formally trained 31 fellows since 1998 (21 pediatricians, 6 pharmacists, 1 advanced practice nurse, 3 PhD scientists).
• The drug biotransformation core serves to characterize drug disposition pathways along with the consequences of drug metabolizing enzyme (DME) polymorphisms in subcellular systems derived from pediatric tissues. A cell culture facility permits fellows and faculty to explore the regulation and expression of DME related proteins. A robust analytical core supports in vitro and in vivo pharmacology- and metabolomics-related research, emphasizing the characterization of developmental trajectories of drug disposition and response pathways. Partnerships with University of Kansas Nuclear Magnetic Resonance (NMR) spectroscopy core allow for the characterization of drug metabolites or biomarker development. The Analytical Chemistry Core Director can provide both didactic and hands‑on instruction to our trainees on quantitative pharmacology methods.
• We have an internationally recognized pharmacogenetics/genomics (PGx) program defining gene sequence variations related to drug disposition and action. This program also administers the Pharmacogene Variation (PharmVar) Consortium. The Pharmacogene Variation (PharmVar) Consortium is a globally recognized central repository for pharmacogene (PGx) variation. The major focus of PharmVar is to catalogue allelic variation of genes impacting drug metabolism, disposition and response and provide a unifying designation system (nomenclature) for the global pharmacogenetic/genomic community.
• A team of dedicated health care providers and researchers in our Clinical Pharmacology Division and Division of Clinical Genetics and Genomics offer an in‑house pharmacogenetic test called Kiddose™ PGx. This test helps clinicians better understand how to dose medications for each specific patient when genetic differences may play a role in their body’s response to pharmaceuticals.
• Quality Improvement projects include Decreasing Turnaround Time of Pharmacogenetic Testing which won a poster award at the UMKC School of Medicine QIPS Day. Currently, there is an ongoing project to Decrease Insurance Preauthorization Time for Pharmacogenetic Testing. Within our faculty roster, we have someone who is an UMKC School of Medicine QIPS Faculty Scholar.

Through strategic team science collaboration with colleagues locally, nationally and internationally, Clinical Pharmacology, Toxicology, and Therapeutic Innovation has leveraged Children’s Mercy strengths in clinical care, genomics, and clinical pharmacology to improve care, enhance research and speed translation of best practice into the community.

The foremost qualities necessary for this position are vision for the field of clinical pharmacology research and patient care. Other desired characteristics include a track record of extramural funding; a history of mentorship that includes developing young investigators into independent scientists; interest in academic infrastructure and research finances; successful collaborations with administration, hospital, medical, and research partners; unwavering commitment to the principles of diversity, equity and inclusion; and commitment to developing a culture of high team accountability and professionalism.

The individual selected for this position will be a strategic and highly communicative leader with a doctoral degree (MD, DO, MD/PhD, DO/PhD, PhD, or PharmD). The Division Director of Clinical Pharmacology, Toxicology & Therapeutic Innovation reports to the Chair of Pediatrics.

• MD, DO, PhD, or PharmD (or combination of degrees) is required
• Current academic rank of Associate Professor or Professor
• A strong record of academic achievement as evidenced by extramural funding in the field of Clinical Pharmacology
• Demonstrated interest in advancing research as it pertains to division activities and interactions with the broader Children’s Mercy community
• A commitment to our true north pillars: quality and safety, people, patient experience, delivery and stewardship
• Fosters and models our values: kindness, curiosity, inclusion, team and integrity
• A deep commitment to fostering and supporting programs that address equity, inclusion and diversity
• A track record of partnership with academic medical centers
• Strong interpersonal skills and the ability and commitment to collaborate with leadership at partner institutions

Nominations and Applications (cover letter and curriculum vitae) should be submitted via e-mail to Facultyjobs@cmh.edu as well as the committee co‑chairs Dr. John Perry (jmperry@cmh.edu) and Dr. Rachel Chevalier Chevalier (rlchevalier@cmh.edu). All materials will be treated as confidential.

Children’s Mercy hires individuals based on their job skills, expertise and ability to maintain professional relationships with fellow employees, patients, parents and visitors. A personal interview, formal education and training, previous work experience, references and a criminal background investigation are all factors used to select the best candidates. The hospital does not discriminate against prospective or current employees based on the race, color, religion, sex, national origin, age, disability, creed, genetic information, sexual orientation, gender identity or expression, ancestry or veteran status. A drug screen will be performed upon hire. Children’s Mercy is smoke and tobacco free. CM is committed to creating a workforce that supports the diverse backgrounds of our patients and families. We know that our greatest strengths come from the people who make up our team, so we hire great people from a wide variety of backgrounds, not just because it’s the right thing to do, but because it makes our hospital stronger and our patient care more compassionate. If you share our values and our enthusiasm for service, you will find a home at CM. In recruiting for our team, we welcome the unique contributions that you can bring, including education, ideas, culture, and beliefs.

Additionally, it is important to us that we remain transparent with all potential job candidates. Because we value the safety of the patients and families we serve, as well as the Children’s Mercy staff, we want to let you know that the seasonal influenza vaccine is a condition of employment for all employees in our organization. New employees must be willing to be vaccinated if found non‑immune to measles, mumps, rubella (MMR) and chickenpox (varicella) and/or without evidence of tetanus, diphtheria, acellular pertussis (Tdap) vaccination since 2005. If you are selected for this position, you will be asked to supply your immunization records as proof of vaccination. If you and have any concerns about receiving these vaccines, medical and/or religious exemptions can be further discussed with Human Resources.

Children’s Mercy is an Equal Opportunity/Affirmative Action Employer. For additional information, please visit our website at www.childrensmercy.org. At Children’s Mercy, we are committed to ensuring that everyone feels welcomed within our walls. A successful candidate for this position will join us as we strive to create a workplace that reflects the community we serve, as well as our core values of kindness, curiosity, inclusion, team and integrity.